Ye Liu

Ye Liu

Auto-generated profile, based on publicly available information

Ye Liu

Breast Surgery Department The First Hospital of China Medical University Shenyang China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
YLYe Liu
Ye Liu
LLLi-Li Li
Li-Li Li
LXLei Xu
Lei Xu
DFDong-Dong Feng
Dong-Dong Feng
YCYu Cao
Yu Cao
BCBo Chen
Bo Chen
Objectives. This meta‐analysis was conducted to compare the complication rates between arm and chest ports in patients with breast cancer. Design and Data Sources. PubMed, Embase, Cochrane library, Chinese National Knowledge Infrastructure (CNKI), and Wanfang database were used to perform a systematic review and meta‐analysis of publications published from the inception of the database to 11, October 2019. Our search generated a total of 22 articles published from 2011 to 2019, including 6 comparative studies and 16 single‐arm articles, involving 4131 cases and 5272 controls. Single‐arm studies combined with comparative studies were also pooled and analyzed. Finally, subgroup analysis was performed to compare the rates of infection and thrombosis between these two ports. Eligibility Criteria. Included articles were research studies comparing complication rates of arm ports with chest ports in patients with breast cancer. Any review or meta‐analysis article would be removed. Data Extraction and Synthesis. Demographic data and information for the following analysis were extracted. DerSimonian and Laird random effect meta‐analysis was conducted to analyze comparative studies while Begg’s and Egger’s tests were used for assessment of publication bias. Meta‐regression analysis was performed to explain the sources of heterogeneity. Results. There was no difference in the risk of overall complications between arm and chest ports for comparative studies (P = 0.083). While results of pooled comparative and single‐arm studies indicated that arm port would increase the overall complication risks with RR of 2.64, results of the subgroup analysis showed that there was no difference in the risk of catheter‐related infection between these two ports. However, arm port might be associated with the higher thrombosis rates compared with chest port according to the results of the analysis for only comparative studies (RR = 2.23, P = 0.041) as well as pooled comparative and single‐arm studies (RR = 1.21, P = 0.029). Conclusions. This study indicated that the arm port might increase the risk of overall complication risks as well as the risk of catheter‐related thrombosis compared with the chest port. However, these reported findings still need to be verified by large randomized clinical trials.

11 March 2021 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
SWShuang-Ling Wu
Shuang-Ling Wu
XZXiaoyi Zhang
Xiaoyi Zhang
MCMengqi Chang
Mengqi Chang
CHChangcai Huang
Changcai Huang
JQJun Qian
Jun Qian
JFJin Feng
Jin Feng
Although DNA 5-hydroxymethylcytosine (5hmC) is recognized as an important epigenetic mark in cancer, its precise role in lymph node metastasis remains elusive. In this study, we investigated how 5hmC associates with lymph node metastasis in breast cancer. Accompanying with high expression of TET1 and TET2 proteins, large numbers of genes in the metastasis-positive primary tumors exhibit higher 5hmC levels than those in the metastasis-negative primary tumors. In contrast, the TET protein expression and DNA 5hmC decrease significantly within the metastatic lesions in the lymph nodes compared to those in their matched primary tumors. Through genome-wide analysis of 8 sets of primary tumors, we identified 100 high-confidence metastasis-associated 5hmC signatures, and it is found that increased levels of DNA 5hmC and gene expression of MAP7D1 associate with high risk of lymph node metastasis. Furthermore, we demonstrate that MAP7D1, regulated by TET1, promotes tumor growth and metastasis. In conclusion, the dynamic 5hmC profiles during lymph node metastasis suggest a link between DNA 5hmC and lymph node metastasis. Meanwhile, the role of MAP7D1 in breast cancer progression suggests that the metastasis-associated 5hmC signatures are potential biomarkers to predict the risk for lymph node metastasis, which may serve as diagnostic and therapeutic targets for metastatic breast cancer.

18 December 2020 in Medicine
Verified
Journal Article
Open access
YLYe Liu
Ye Liu
YWYangbin Wang
Yangbin Wang
RQRuiqun Qi
Ruiqun Qi
XMXiaoyun Mao
Xiaoyun Mao
JFJin Feng
Jin Feng
Backgound: This study aims to identify the expression of lipoma preferred partner (LPP) in Paget disease (PD) and to further understand the pathogenesis of PD. Methods: Tissue microarray was used to evaluate the expression of LPP by immunohistochemistry in 40 PD patients. The results of LPP expression were combined with clinical and histopathological characteristics. Patient files were analyzed retrospectively. Results: Twenty-one cases were mammary Paget disease (MPD) and 19 extramammary Paget disease (EMPD) involving the vulva, scrotum, and penis. LPP was expressed in PD and this expression was significantly greater in MPD versus EMPD (P = .031). The expression of LPP in MPD was significantly related with age (P = .009) and expression of Ki-67 (P = .011). No statistically significant differences were observed in LPP expression as related to sex, body location, and time of PD diagnosis. Conclusions: While LPP is expressed in both MPD and EMPD, the intensity of this expression is greater in MPD. LPP expression is positively correlated with Ki-67 and is more prevalent in middle-aged versus senior MPD patients. Further research is needed to determine its potential role in tumorigenesis and distribution.

2 March 2021 in JMIR Medical Informatics
Verified
Journal Article
Open access
JMJinfei Ma
Jinfei Ma
ZZZihao Zou
Zihao Zou
Emmanuel Eric PazoEmmanuel Eric Pazo
Emmanuel Eric Pazo
SMSalissou Moutari
Salissou Moutari
YLYe Liu
Ye Liu
JFJin Feng
Jin Feng
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Breast cancer remains the most common neoplasm diagnosed amongst women in China and globally. Health-related questionnaire assessments in research and clinical oncology settings have gained prominence. National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16) is a rapid and powerful tool to help evaluate the disease or treatment-related symptoms, both physical and emotional, in patients with breast cancer for clinical and research need. Prevalence of individual smartphones provides a potential web-based approach to administrating questionnaire; however, the reliability of NFBSI-16 in electronic format has not been assessed. Objective: This study aimed to assess the reliability of web-based NFBSI-16 questionnaire in breast cancer patients undergoing systematic treatment with a prospective open-label randomised crossover study design. Methods: We recruited random patients from the central hospital registry with breast cancer under systematic treatment to complete both paper- and web-based versions of the questionnaires. Both versions of the questionnaires were self-assessed. Patients were randomly assigned to group A (paper- based first and web-based second) or group B (web- based first and paper-based second). A total of 354 patients were included in the analysis (group A: n= 177, group B: n=177). Descriptive sociodemographic characteristics, reliability and agreement rates for single items, subscale, and total score were analysed using Wilcoxon test. Lin’s concordance correlation coefficient (CCC), Spearman and Kendall tau rank correlation were used to assess test-retest reliability. Results: Test-retest reliability was measured with CCCs was 0.94 for the total NFBSI-16 score. Significant correlations (Spearman's rho) were documented for all 4 subscales: DRS-P (rho=0.93), DRS-E (rho=0.85), TSE (rho=0.95), and FWB (rho=0.91) and total NFBSI-16 score (rho=0.94). Mean differences of the test and re-test were all close to zero (≤0.06). The parallel test-retest reliability of subscales with Wilcoxon test comparing individual items found GP3 (Item 5) to be significantly different (P=0.02). A majority of the participants in this study preferred the web-based (72%, n=255) over the paper-based version. Conclusions: The web-based version of the NFBSI-16 questionnaire is an excellent tool for monitoring individual breast cancer patients under treatment, with majority of participants preferring it over paper-based version.

16 February 2020 in JMIR Preprints
Verified
Preprint
Open access
JMJinfei Ma
Jinfei Ma
ZZZihao Zou
Zihao Zou
Emmanuel Eric PazoEmmanuel Eric Pazo
Emmanuel Eric Pazo
SMSalissou Moutari
Salissou Moutari
YLYe Liu
Ye Liu
JFJin Feng
Jin Feng
BACKGROUND Breast cancer remains the most common neoplasm diagnosed among women in China and globally. Health-related questionnaire assessments in research and clinical oncology settings have gained prominence. The National Comprehensive Cancer Network–Functional Assessment of Cancer Therapy–Breast Cancer Symptom Index (NFBSI-16) is a rapid and powerful tool to help evaluate disease- or treatment-related symptoms, both physical and emotional, in patients with breast cancer for clinical and research purposes. Prevalence of individual smartphones provides a potential web-based approach to administrating the questionnaire; however, the reliability of the NFBSI-16 in electronic format has not been assessed. OBJECTIVE This study aimed to assess the reliability of a web-based NFBSI-16 questionnaire in breast cancer patients undergoing systematic treatment with a prospective open-label randomized crossover study design. METHODS We recruited random patients with breast cancer under systematic treatment from the central hospital registry to complete both paper- and web-based versions of the questionnaires. Both versions of the questionnaires were self-assessed. Patients were randomly assigned to group A (paper-based first and web-based second) or group B (web-based first and paper-based second). A total of 354 patients were included in the analysis (group A: n=177, group B: n=177). Descriptive sociodemographic characteristics, reliability and agreement rates for single items, subscales, and total score were analyzed using the Wilcoxon test. The Lin concordance correlation coefficient (CCC) and Spearman and Kendall τ rank correlations were used to assess test-retest reliability. RESULTS Test-retest reliability measured with CCCs was 0.94 for the total NFBSI-16 score. Significant correlations (Spearman ρ) were documented for all 4 subscales—Disease-Related Symptoms Subscale–Physical (ρ=0.93), Disease-Related Symptoms Subscale–Emotional (ρ=0.85), Treatment Side Effects Subscale (ρ=0.95), and Function and Well-Being Subscale (ρ=0.91)—and total NFBSI-16 score (ρ=0.94). Mean differences of the test and retest were all close to zero (≤0.06). The parallel test-retest reliability of subscales with the Wilcoxon test comparing individual items found GP3 (item 5) to be significantly different (P=.02). A majority of the participants in this study (255/354, 72.0%) preferred the web-based over the paper-based version. CONCLUSIONS The web-based version of the NFBSI-16 questionnaire is an excellent tool for monitoring individual breast cancer patients under treatment, with the majority of participants preferring it over the paper-based version.

2 December 2025 in Psycho-Oncology
Verified
Journal Article
Closed access
KZKaina Zhou
Kaina Zhou
LYLi Yang
Li Yang
LYLing Yuan
Ling Yuan
LZLisha Zhang
Lisha Zhang
DPDong Pang
Dong Pang
YLYe Liu
Ye Liu